share_log

Processa Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Processa Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Processa Pharmaceuticals | 10-Q：2024財年二季報
美股SEC公告 ·  08/13 16:20

Moomoo AI 已提取核心訊息

Processa Pharmaceuticals, Inc. (Processa), a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company's cash and cash equivalents increased to $5,571,120 from $4,706,197 at the end of the previous year. Total assets rose to $7,600,976, up from $5,786,643. Research and development expenses for the quarter were $1,730,444, slightly up from $1,688,164 in the same period last year, while general and administrative expenses increased to $1,351,580 from $1,026,301. The company reported a net loss of $3,010,326 for the quarter, compared to a net loss of $2,612,565 in the previous year. The net loss per common share was $1.01, compared to $1.94 in the same quarter of the previous year. Processa continues to focus on the development of its Next Generation Chemotherapy (NGC) drugs, with a Phase 2 trial for NGC-Cap in breast cancer expected to begin shortly. The company's future plans include advancing its pipeline of NGC proprietary small molecule oncology drugs and exploring options to monetize non-core drug assets through out-licensing or partnerships.
Processa Pharmaceuticals, Inc. (Processa), a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company's cash and cash equivalents increased to $5,571,120 from $4,706,197 at the end of the previous year. Total assets rose to $7,600,976, up from $5,786,643. Research and development expenses for the quarter were $1,730,444, slightly up from $1,688,164 in the same period last year, while general and administrative expenses increased to $1,351,580 from $1,026,301. The company reported a net loss of $3,010,326 for the quarter, compared to a net loss of $2,612,565 in the previous year. The net loss per common share was $1.01, compared to $1.94 in the same quarter of the previous year. Processa continues to focus on the development of its Next Generation Chemotherapy (NGC) drugs, with a Phase 2 trial for NGC-Cap in breast cancer expected to begin shortly. The company's future plans include advancing its pipeline of NGC proprietary small molecule oncology drugs and exploring options to monetize non-core drug assets through out-licensing or partnerships.
臨床階段生物製藥公司Processa Pharmaceuticals, Inc.（Processa）報告了2024年6月30日結束的季度財務狀況。該公司的現金及現金等價物從上年末的$4,706,197增至$5,571,120。總資產從$5,786,643上升至$7,600,976。本季度的研發費用爲$1,730,444，略高於上年同期的$1,688,164，而總行政費用從$1,026,301增加至$1,351,580。該公司報告本季度淨虧損爲$3,010,326，而上年同期淨虧損爲$2,612,565。每股普通股淨虧損爲$1.01，而上年同季度爲$1.94。Processa繼續專注於其Next Generation Chemotherapy (NGC)藥物的開發，預計很快將開始NGC-Cap用於乳腺癌的第二階段試驗。公司的未來計劃包括推進其NGC專有小分子腫瘤藥物流水線並探索通過外部授權或合作伙伴關係獲取非核心藥物資產的獲利選擇。
臨床階段生物製藥公司Processa Pharmaceuticals, Inc.（Processa）報告了2024年6月30日結束的季度財務狀況。該公司的現金及現金等價物從上年末的$4,706,197增至$5,571,120。總資產從$5,786,643上升至$7,600,976。本季度的研發費用爲$1,730,444，略高於上年同期的$1,688,164，而總行政費用從$1,026,301增加至$1,351,580。該公司報告本季度淨虧損爲$3,010,326，而上年同期淨虧損爲$2,612,565。每股普通股淨虧損爲$1.01，而上年同季度爲$1.94。Processa繼續專注於其Next Generation Chemotherapy (NGC)藥物的開發，預計很快將開始NGC-Cap用於乳腺癌的第二階段試驗。公司的未來計劃包括推進其NGC專有小分子腫瘤藥物流水線並探索通過外部授權或合作伙伴關係獲取非核心藥物資產的獲利選擇。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間